About Dyne Therapeutics, Inc.
https://www.dyne-tx.comDyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
CEO
John G. Cox
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 137
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Raymond James
Strong Buy
Stifel
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Evercore ISI Group
Outperform
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:14.75M
Value:$257.31M
VANGUARD GROUP INC
Shares:9.76M
Value:$170.32M
BLACKROCK, INC.
Shares:9.63M
Value:$168.13M
Summary
Showing Top 3 of 228
About Dyne Therapeutics, Inc.
https://www.dyne-tx.comDyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $113.89M ▼ | $-108.04M ▲ | 0% | $-0.76 ▲ | $-104.61M ▲ |
| Q2-2025 | $0 | $115.79M ▼ | $-110.86M ▲ | 0% | $-0.97 ▲ | $-110.26M ▲ |
| Q1-2025 | $0 | $122.37M ▲ | $-115.36M ▼ | 0% | $-1.05 ▼ | $-121.87M ▼ |
| Q4-2024 | $0 | $97.11M ▼ | $-89.54M ▲ | 0% | $-0.88 ▲ | $-96.66M ▲ |
| Q3-2024 | $0 | $105.66M | $-97.13M | 0% | $-0.96 | $-105.22M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $791.89M ▲ | $867.06M ▲ | $175.28M ▲ | $691.78M ▲ |
| Q2-2025 | $683.92M ▲ | $728.99M ▲ | $157.55M ▲ | $571.45M ▼ |
| Q1-2025 | $677.49M ▲ | $721.07M ▲ | $52.1M ▼ | $668.97M ▲ |
| Q4-2024 | $642.27M ▼ | $691.23M ▼ | $61.4M ▼ | $629.84M ▼ |
| Q3-2024 | $723.67M | $768.84M | $63.3M | $705.54M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-108.04M ▲ | $-90.78M ▲ | $-37.97M ▼ | $217.33M ▲ | $88.57M ▲ | $-109.96M ▼ |
| Q2-2025 | $-110.86M ▲ | $-94.7M ▲ | $6.77M ▲ | $100.77M ▼ | $12.85M ▼ | $-94.76M ▲ |
| Q1-2025 | $-115.36M ▼ | $-105.89M ▼ | $1.46M ▲ | $141.24M ▲ | $36.81M ▲ | $-106.87M ▼ |
| Q4-2024 | $-89.54M ▲ | $-84.33M ▼ | $-16.01M ▲ | $3.64M ▼ | $-96.71M ▼ | $-85.41M ▼ |
| Q3-2024 | $-97.13M | $-74.63M | $-19.4M | $18.01M | $-76.02M | $-74.88M |
CEO
John G. Cox
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 137
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Raymond James
Strong Buy
Stifel
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Guggenheim
Buy
Evercore ISI Group
Outperform
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:14.75M
Value:$257.31M
VANGUARD GROUP INC
Shares:9.76M
Value:$170.32M
BLACKROCK, INC.
Shares:9.63M
Value:$168.13M
Summary
Showing Top 3 of 228